Moderna, Inc.’s stock price takes a hit, dropping 5.62% to $37.29: Is it time to buy?

Moderna, Inc. (MRNA)

37.29 USD -2.22 (-5.62%) Volume: 8.96M

Moderna, Inc.’s stock price stands at 37.29 USD, witnessing a decline of 5.62% in the current trading session with a trading volume of 8.96M. The biotechnology company’s stock has suffered a substantial decrease of 62.50% year-to-date, reflecting its turbulent performance in the market.

Latest developments on Moderna, Inc.

Despite political concerns over vaccine safety and the HHS nomination, Moderna remains confident as its stock price movements today reflect a mix of upgrades and downgrades from various financial institutions. Berenberg initiated coverage on Moderna and BioNTech, starting the former at hold and the latter at buy. HSBC upgraded Moderna to a buy rating based on its pipeline potential, while Piper Sandler lowered the price target for Moderna to $69 from $115. Despite the fluctuations, Moderna’s stock climbed after the HSBC upgrade, indicating optimism in the market regarding the company’s future prospects.

Moderna, Inc. on Smartkarma

Analysts at Baptista Research have published a bullish report on Moderna, highlighting the company’s recent Quarterly Earnings performance. The report mentions advancements in Moderna’s respiratory vaccine portfolio, particularly with mRNA-1273, its COVID-19 vaccine, and new RSV vaccine, mRESVIA. mRNA-1273 continues to be a significant product in combating COVID-19, with substantial hospitalization rates reported from the CDC for the ’23/’24 season.

To read more about Moderna Inc.’s performance and the challenges that bears are counting on, check out the full report by Baptista Research on Smartkarma. The report provides valuable insights into the major drivers affecting Moderna’s stock and the potential risks investors should be aware of. Stay informed with independent analysis from top analysts on Smartkarma to make well-informed investment decisions.

A look at Moderna, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Moderna, Inc. is showing promise in the long-term outlook based on the Smartkarma Smart Scores. With a high Value score of 4, the company is considered to have strong potential for growth and profitability. Additionally, Moderna has a Resilience score of 3, indicating its ability to withstand market fluctuations and challenges. Despite lower scores in Dividend and Momentum, the company’s focus on mRNA therapeutics and vaccines for various diseases positions it well for future success.

As a biotechnology company, Moderna, Inc. is leveraging its expertise in messenger RNA technology to develop innovative medicines. While the company may have room for improvement in areas like Growth and Momentum, its dedication to advancing treatments for infectious, immuno-oncology, and cardiovascular diseases is commendable. Investors and analysts are optimistic about Moderna’s potential based on its Smartkarma Smart Scores, highlighting the company’s strong value and resilience in the competitive biotech industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma